Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EssilorluxotticaESLOY +0.72%82 EV-to-EBITDA is 12.80 as of Jul. 26, 2026, which is 21% below its 10-year median of 16.17. GuruFocus rates ESLOY with a GF Score™ of 82/100 and a GF Value™ of $133.35 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Essilorluxottica ranks better than 54.9% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Essilorluxottica's enterprise value is $98,096 Mil.
Essilorluxottica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $7,664 Mil. Therefore, Essilorluxottica's EV-to-EBITDA for today is 12.80.
The historical rank and industry rank for Essilorluxottica's EV-to-EBITDA or its related term are showing as below:
ESLOY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.41 Med: 16.17 Max: 33.89
Current: 13.12
During the past 13 years, the highest EV-to-EBITDA of Essilorluxottica was 33.89. The lowest was 11.41. And the median was 16.17.
ESLOY's EV-to-EBITDA is ranked better than 54.9% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 13.845
vs ESLOY: 13.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Essilorluxottica's PE Ratio (TTM) for today is calculated as:
Essilorluxottica's share price for today is $92.54.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Essilorluxottica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.889.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Essilorluxottica's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Essilorluxottica's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essilorluxottica EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Essilorluxottica's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Essilorluxottica's EV-to-EBITDA falls into.
Essilorluxottica's current Enterprise Value is $98,096 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Essilorluxottica's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $7,664 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essilorluxottica (ESLOY) has a EV-to-EBITDA of 12.80 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Essilorluxottica. This is 21% below median its historical median of 16.17. Over the past decade, Essilorluxottica's EV-to-EBITDA has ranged from 11.41 to 33.89. According to the industry distribution chart, Essilorluxottica ranks #230 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 45.1%.
Is Essilorluxottica's EV-to-EBITDA too high?
Essilorluxottica's current EV-to-EBITDA of 12.80 is 21% below median its 10-year median of 16.17. Over the past 10 years, this metric has ranged from a low of 11.41 to a high of 33.89. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.85. Essilorluxottica's value of 12.80 is 7.5% below this industry median. Based on the distribution chart, Essilorluxottica ranks #230 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Essilorluxottica has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essilorluxottica's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Essilorluxottica ranks #230 out of 510 companies for EV-to-EBITDA. This puts Essilorluxottica in the upper half of its industry. The industry median EV-to-EBITDA is 13.85. Essilorluxottica's value of 12.80 is 7.5% below this benchmark. Historically, Essilorluxottica's own EV-to-EBITDA has ranged from 11.41 to 33.89 over the past decade. While the company's 10-year median is 16.17 vs. the industry median of 13.85, Essilorluxottica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.85, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essilorluxottica's current EV-to-EBITDA of 12.80 is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Essilorluxottica. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essilorluxottica's current EV-to-EBITDA is 12.80, which is 21% below median its own 10-year median of 16.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essilorluxottica stock overvalued right now?
Based on GuruFocus' analysis, Essilorluxottica (ESLOY) is currently considered Significantly Undervalued. The stock's GF Value™ is $133.35, compared to a current price of $92.54 — trading 30.6% below its estimated fair value. The current EV-to-EBITDA is 12.80, which is 21% below median its 10-year median of 16.17 and 7.5% below the Medical Devices & Instruments industry median of 13.85. Essilorluxottica's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Essilorluxottica (ESLOY), the current EV-to-EBITDA is 12.80 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essilorluxottica (ESLOY) Overvalued in 2026?
Based on GuruFocus' analysis, Essilorluxottica stock appears to be undervalued.
The current stock price of $92.54 is trading 30.6% below its estimated GF Value™ of $133.35.
GuruFocus considers Essilorluxottica to be Significantly Undervalued.
Key valuation signals for ESLOY:
EV-to-EBITDA: 12.80 (21% below median its 10-year median of 16.17)
GF Value™: $133.35 vs. price of $92.54 (30.6% below fair value)
Industry Position: 7.5% below the Medical Devices & Instruments median (#230 of 510)
No single metric tells the full story. See the ESLOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EssilorLuxottica is a combination of the leading manufacturer of premium frames and sunglasses and the leading manufacturer of optical lenses. Both companies are significantly larger than the next biggest competitor and command over 15% of the fragmented global eyewear market. The company has a broad geographical presence, with around 37% of sales in Europe, 45% in North America, and the rest in Asia and Latin America.
82GF Score
Get the complete analysis for ESLOY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESLOY has been successfully added to your 
